Loading
The nuclear medicine physician who founded and leads Excel Diagnostics in Houston, a radiopharmaceutical therapy centre that also runs early trials of new radioligands.
Ebrahim Delpassand is Chief Executive Officer and medical director of Excel Diagnostics and Nuclear Oncology Center in Houston, which its site describes as a Radiopharmaceutical Therapy Center of Excellence designated by the Society of Nuclear Medicine and Molecular Imaging, offering PET-CT and other imaging, radionuclide therapy and clinical trials. He has been an investigator on early trials of somatostatin and PSMA radioligands. His publications are listed on PubMed.
Shares PSMA PET, Radioligand therapy (beta emitters) and the tag leadership.